#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	17648	16S	1529	1529	99.93	16S.l15.c17.ctg.1	2307	925.9	0	.	n	.	0	C1450T	SNP	1450	1450	C	1726	1726	T	1171	T,G,C	1169,1,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	17648	16S	1529	1529	99.93	16S.l15.c17.ctg.1	2307	925.9	1	SNP	n	C1184T	0	.	.	1184	1184	C	1460	1460	C	1177	C,A	1175,2	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	30216	23S	2890	2890	99.93	23S.l6.c4.ctg.1	4028	934.7	0	.	n	.	0	G1337A	SNP	1337	1337	G	1916	1916	A	1222	A,G	1221,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	30216	23S	2890	2890	99.93	23S.l6.c4.ctg.1	4028	934.7	0	.	n	.	0	T1971C	SNP	1971	1971	T	2550	2550	C	1142	C,T,A	1140,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	30216	23S	2890	2890	99.93	23S.l6.c4.ctg.1	4028	934.7	1	SNP	n	A2045G	0	.	.	2045	2045	A	2624	2624	A	1061	A	1059	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	30216	23S	2890	2890	99.93	23S.l6.c4.ctg.1	4028	934.7	1	SNP	n	C2597T	0	.	.	2597	2597	C	3176	3176	C	1060	C,G,T	1057,2,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_Y_01480c	folP.WHO_Y_01480c	1	1	27	2614	folP	855	855	100.0	folP.l6.c17.ctg.1	1852	175.2	1	SNP	p	R229S	1	.	.	685	687	AGC	1108	1110	AGC	287;283;285	A;G;C	287;283;285	folP.WHO_Y_01480c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	6420	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3747	213.2	1	SNP	p	S91F	1	.	.	271	273	TTC	721	723	TTC	258;260;263	T,A;T,G,C;C	257,1;258,1,1;263	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	6420	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3747	213.2	1	SNP	p	D95G	1	.	.	283	285	GGC	733	735	GGC	263;267;268	G,T;G,A;C	262,1;266,1;268	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	6420	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3747	213.2	1	SNP	p	G95N	0	.	.	283	285	GGC	733	735	GGC	263;267;268	G,T;G,A;C	262,1;266,1;268	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	27	2438	mtrR	633	633	100.0	mtrR.l6.c30.ctg.1	1747	174.0	1	SNP	p	G45D	0	.	.	133	135	GGC	628	630	GGC	296;292;292	G,C;G,A;C,T	295,1;291,1;291,1	mtrR.WHO_O_01438:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	1384	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1435	120.1	0	.	n	.	0	A197.	DEL	197	197	A	812	812	A	261	A	261	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	5778	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3347	215.1	0	.	p	.	0	I384V	NONSYN	1150	1152	ATC	1660	1662	GTC	261;259;260	G;T;C,A	261;259;259,1	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	5778	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3347	215.1	1	SNP	p	D86N	0	.	.	256	258	GAC	766	768	GAC	271;270;268	G;A,T;C	271;269,1;268	parC.WHO_V_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	5778	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3347	215.1	1	SNP	p	S87R	1	.	.	259	261	CGT	769	771	CGT	269;271;271	C,G;G,T;T	268,1;270,1;271	parC.WHO_V_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	5778	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3347	215.1	1	SNP	p	R87W	0	.	.	259	261	CGT	769	771	CGT	269;271;271	C,G;G,T;T	268,1;270,1;271	parC.WHO_V_00204c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	5778	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3347	215.1	1	SNP	p	R87I	0	.	.	259	261	CGT	769	771	CGT	269;271;271	C,G;G,T;T	268,1;270,1;271	parC.WHO_V_00204c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	5778	parC	2304	2304	99.87	parC.l15.c4.ctg.1	3347	215.1	1	SNP	p	S88P	0	.	.	262	264	TCC	772	774	TCC	268;266;266	T,G;C,T;C	267,1;265,1;266	parC.WHO_V_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	5304	parE	1986	1986	99.95	parE.l15.c4.ctg.1	3088	213.9	0	.	p	.	0	R340C	NONSYN	1018	1020	CGC	1536	1538	TGC	256;255;256	T,G;G;C	255,1;255;256	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	5304	parE	1986	1986	99.95	parE.l15.c4.ctg.1	3088	213.9	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1746	1748	GGC	300;297;297	G;G;C,A	300;297;296,1	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.12.001	penA.12.001	1	1	27	4600	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2782	205.9	1	SNP	p	A311V	0	.	.	931	933	GCA	1448	1450	GCA	275;277;277	G;C;A	275;277;277	penA.12.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4600	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2782	205.9	1	SNP	p	I312M	0	.	.	934	936	ATC	1451	1453	ATC	275;273;272	A;T;C	275;273;272	penA.12.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4600	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2782	205.9	1	SNP	p	V316P	0	.	.	946	948	GTG	1463	1465	GTG	269;267;268	G;T;G	269;266;268	penA.12.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4600	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2782	205.9	1	SNP	p	V316T	0	.	.	946	948	GTG	1463	1465	GTG	269;267;268	G;T;G	269;266;268	penA.12.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4600	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2782	205.9	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1967	1969	ACC	299;300;297	A;C;C	299;300;297	penA.12.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4600	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2782	205.9	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2021	2023	GCG	256;262;260	G;C;G	256;261;259	penA.12.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4600	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2782	205.9	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2021	2023	GCG	256;262;260	G;C;G	256;261;259	penA.12.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4600	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2782	205.9	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2144	2146	GGC	244;241;241	G;G,A,T;C,G	244;239,1,1;239,1	penA.12.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4600	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2782	205.9	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2153	2155	GGC	234;236;239	G,C;G;C	233,1;236;239	penA.12.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4600	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2782	205.9	1	SNP	p	P552S	1	.	.	1654	1656	TCG	2171	2173	TCG	262;262;264	T;C,T;G,C	262;261,1;263,1	penA.12.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	6612	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3462	237.6	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1751	1753	CCG	271;272;271	C;C;G,T,A	271;272;269,1,1	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	3000	porA	1146	1146	99.56	porA.l15.c4.ctg.1	2167	172.5	0	.	p	.	0	M83fs	FSHIFT	247	247	A	742	742	C	228	C	228	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	340	porB1a	984	156	92.95	porB1a.l15.c30.ctg.1	156	60.1	0	.	p	.	0	V258L	NONSYN	772	774	GTA	14	16	TTA	36;40;41	T;T;A	36;40;41	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	340	porB1a	984	156	92.95	porB1a.l15.c30.ctg.1	156	60.1	0	.	p	.	0	Y273H	NONSYN	817	819	TAT	59	61	CAT	75;75;75	C;A;T	75;75;75	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	340	porB1a	984	156	92.95	porB1a.l15.c30.ctg.1	156	60.1	0	.	p	.	0	D274S	NONSYN	820	822	GAT	62	64	AGT	75;75;75	A;G;T,G	75;75;74,1	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	340	porB1a	984	156	92.95	porB1a.l15.c30.ctg.1	156	60.1	0	.	p	.	0	N277Y	NONSYN	829	831	AAC	71	73	TAC	75;75;75	T;A,C;C	75;74,1;75	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3286	porB1b	1047	1047	99.33	porB1b.l6.c17.ctg.1	1860	218.9	0	.	p	.	0	N38E	NONSYN	112	114	AAT	550	552	GAA	277;276;273	G,C;A;A	276,1;276;273	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3286	porB1b	1047	1047	99.33	porB1b.l6.c17.ctg.1	1860	218.9	0	.	p	.	0	N134D	NONSYN	400	402	AAT	838	840	GAT	281;283;285	G;A,G;T,A	281;282,1;284,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3286	porB1b	1047	1047	99.33	porB1b.l6.c17.ctg.1	1860	218.9	0	.	p	.	0	P175S	NONSYN	523	525	CCA	961	963	TCA	282;282;286	T;C;A,C	282;282;285,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3286	porB1b	1047	1047	99.33	porB1b.l6.c17.ctg.1	1860	218.9	0	.	p	.	0	A218V	NONSYN	652	654	GCC	1090	1092	GTC	313;312;308	G,A,T;T;C,A	311,1,1;312;307,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3286	porB1b	1047	1047	99.33	porB1b.l6.c17.ctg.1	1860	218.9	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1420	1422	GCA	268;272;275	G;C;A	268;272;275	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3286	porB1b	1047	1047	99.33	porB1b.l6.c17.ctg.1	1860	218.9	1	SNP	p	G120K	1	.	.	358	360	AAG	796	798	AAG	285;289;289	A;A;G	285;288;288	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3286	porB1b	1047	1047	99.33	porB1b.l6.c17.ctg.1	1860	218.9	1	SNP	p	A121D	1	.	.	361	363	GAC	799	801	GAC	289;290;292	G;A,T,G;C	288;287,1,1;291	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3286	porB1b	1047	1047	99.33	porB1b.l6.c17.ctg.1	1860	218.9	1	SNP	p	D121N	0	.	.	361	363	GAC	799	801	GAC	289;290;292	G;A,T,G;C	288;287,1,1;291	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	11920	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	5243	283.4	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2193	2195	AAT	321;317;317	A,C;A,G;T	320,1;316,1;317	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1776	rpsJ	312	312	100.0	rpsJ.l6.c4.ctg.1	1450	152.5	1	SNP	p	V57M	1	.	.	169	171	ATG	681	683	ATG	286;286;285	A;T;G	286;286;285	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
